肝细胞癌综合治疗研究进展

doi:10.19538/j.cjps.issn1005-2208.2025.10.22

中国实用外科杂志 ›› 2025, Vol. 45 ›› Issue (10) : 1186-1190. DOI: 10.19538/j.cjps.issn1005-2208.2025.10.22

文献综述

肝细胞癌综合治疗研究进展

张维志1，刘连新1,2

作者信息 +

文章历史 +

摘要

肝细胞癌是我国重点攻坚的恶性肿瘤之一，其5年生存率仍有待提高。早期诊断与分期导向的全程管理是改善预后的关键措施。对于早期病人，根治性手术仍是实现长期生存的主要手段，术后辅助治疗策略日益趋向精准化与个体化。中晚期肝癌则强调转化治疗以及局部与系统治疗的联合应用。近年来，系统治疗的快速发展显著改善了晚期肝癌病人的生存，也不断重塑着肝癌的治疗格局。目前，晚期肝癌的治疗模式已逐渐演变为以免疫治疗为基石的联合治疗。肝癌综合治疗正呈现出“局部治疗精准化、系统治疗前移化、全程管理个体化”的趋势。在多学科综合治疗协作组模式下，结合肿瘤分期、分子特征及病人全身情况等多因素制定个体化治疗方案，对于进一步提升肝癌病人生存率具有重要意义。

Abstract

Hepatocellular carcinoma (HCC) is one of the major malignancies under intensive control efforts in China, with a five-year survival rate remains to be improved. Early diagnosis and stage-guided comprehensive management are key measures to improve prognosis. For early-stage patients, curative surgery remains the primary approach to achieving long-term survival, while postoperative adjuvant therapies are increasingly moving toward precision and individualization. For intermediate and advanced stages, emphasis has shifted to conversion therapy and the combined use of locoregional and systemic treatments. In recent years, the rapid advancement of systemic therapies has significantly improved survival in advanced HCC and reshaped the therapeutic landscape. At present, treatment paradigm for advanced HCC has gradually evolved toward immunotherapy-based combination regimens. Overall, comprehensive management of HCC is trending toward “precision in locoregional therapy, earlier application of systemic therapy, and individualized full-course management”. Within the multidisciplinary team framework, individualized strategies that integrate tumor stage, molecular characteristics, and patient condition are of critical importance for further improving survival outcomes.

导出引用

张维志1, 刘连新1, 2. 肝细胞癌综合治疗研究进展[J]. 中国实用外科杂志. 2025, 45(10): 1186-1190 https://doi.org/10.19538/j.cjps.issn1005-2208.2025.10.22

参考文献

［1］国家卫生健康委办公厅. 原发性肝癌诊疗指南（2024年版）［J］. 中国实用外科杂志, 2024, 44(4): 361-386. DOI: 10.19538/j.cjps.issn1005-2208.2024.04.01.
［2］ Zeng H, Zheng R, Sun K, et al. Cancer survival statistics in China 2019-2021: A multicenter, population-based study ［J］. J Natl Cancer Cent, 2024, 4(3): 203-213. DOI: 10.1016/j.jncc.2024.06.005.
［3］张维志, 刘连新. 肝细胞癌解剖性肝切除的规范与进展［J］. 中华肝胆外科杂志, 2024, 30(2): 151-155. DOI: 10.3760/cma.j.cn113884-20230830-00054.
［4］ Wang Z, Ren Z, Chen Y, et al. Adjuvant transarterial chemoembolization for HBV-related hepatocellular carcinoma after resection: A randomized controlled study ［J］. Clin Cancer Res, 2018, 24(9): 2074-2081. DOI: 10.1158/1078-0432.CCR-17-2899.
［5］ Li S , Mei J, Cheng Y, et al. Postoperative adjuvant hepatic arterial infusion chemotherapy with FOLFOX in hepatocellular carcinoma with microvascular invasion: A multicenter, phase Ⅲ，randomized study ［J］. J Clin Oncol，2023，41(10): 1898-1908. DOI: 10.1200/JCO.22.01142.
［6］ Shi C, Li Y, Geng L, et al. Adjuvant stereotactic body radiotherapy after marginal resection for hepatocellular carcinoma with microvascular invasion: A randomised controlled trial ［J］. Eur J Cancer，2022，166: 176-184. DOI: 10.1016/j.ejca.2022.02.012.
［7］ Bruix J, Takayama T, Mazzaferro V, et al. Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): A phase 3, randomised, double-blind, placebo-controlled trial ［J］. Lancet Oncol, 2015, 16(13): 1344-1354. DOI: 10.1016/S1470-2045(15)00198-9.
［8］ Sun H , Zhu X , Zhou J, et al. Adjuvant apatinib treatment after resection of hepatocellular carcinoma with portal vein tumor thrombosis: A phase Ⅱ trial ［J］. Ann Transl Med, 2020, 8(20): 1301. DOI: 10.21037/atm-20-6181.
［9］ Bai S, Hu L, Liu J, et al. Prognostic nomograms combined adjuvant lenvatinib for hepatitis B virus-related hepatocellular carcinoma with microvascular invasion after radical resection ［J］. Front Oncol, 2022, 12: 919824. DOI: 10.3389/fonc.2022.919824.
［10］ Wang K, Xiang Y, Yu H, et al. Adjuvant sintilimab in resected high-risk hepatocellular carcinoma: a randomized, controlled, phase 2 trial ［J］. Nat Med, 2024, 30(3): 708-715. DOI: 10.1038/s41591-023-02786-7.
［11］ Yopp A, Kudo M, Chen M, et al. LBA39 Updated efficacy and safety data from IMbrave050: Phase Ⅲ study of adjuvant atezolizumab (atezo) + bevacizumab (bev) vs active surveillance in patients (pts) with resected or ablated high-risk hepatocellular carcinoma (HCC) ［J］. Ann Oncol, 2024, 35：S1230. DOI: 10.1016/j.annonc.2024.08.2279.
［12］ Peng Z, Fan W, Liu Z, et al. Adjuvant transarterial chemoembolization with sorafenib for portal vein tumor thrombus: A randomized clinical trial ［J］. JAMA Surg, 2024, 159(6): 616-624. DOI: 10.1001/jamasurg.2024.0506.
［13］ Guo D, Zhang S, Gu Z, et al. Utilization of tumor-informed circulating tumor DNA in detecting minimal residual disease and guiding adjuvant therapy in liver cancer ［J］. J Clin Oncol, 2024, 42(suppl16): 4125. DOI: 10.1200/JCO.2024.42.16_suppl.4125.
［14］ Jia G, He P, Dai T, et al. Spatial immune scoring system predicts hepatocellular carcinoma recurrence［J］. Nature，2025，640(8060): 1031-1041. DOI: 10.1038/s41586-025-08668-x
［15］ Zhang S, Song R, Hou C, et al. Simultaneous liver venous deprivation following hepatic arterial chemoembolization before major hepatectomy for hepatocellular carcinoma: A new methods to achieve hypertrophy liver remnant ［J］. J Hepatocell Carcinoma, 2025, 12: 219-229. DOI: 10.2147/JHC.S495304.
［16］ Hamad A, Aziz H, Kamel IR, et al. Yttrium-90 radioembolization: current indications and outcomes［J］. J Gastrointest Surg. 2023, 27(3): 604-614. DOI: 10.1007/s11605-022-05559-8.
［17］ Liu J, Zhu X, Pan Y, et al. Prognoses of patients treated with surgical therapy versus continuation of local-plus-systemic therapy following successful down-staging of intermediate-advanced hepatocellular carcinoma: A multicenter real-world study［J］. Oncologist, 2024, 29(4): e487-e497. DOI: 10.1093/oncolo/oyad277.
［18］ Chiang CL, Chan KSK, Chiu KWH, et al. Complete response to locoregional therapy plus immunotherapy for hepatocellular carcinoma ［J］. JAMA Oncol, 2024, 10(11): 1548-1553. DOI: 10.1001/jamaoncol.2024.4085.
［19］ Scheiner B, Kang B, Balcar L, et al. Outcome and management of patients with hepatocellular carcinoma who achieved a complete response to immunotherapy-based systemic therapy ［J］. Hepatology，2025，81(6): 1714-1727. DOI: 10.1097/HEP.0000000000001163.
［20］ Li B, Wang C, He W, et al. Watch-and-wait strategy vs. resection in patients with radiologic complete response after conversion therapy for initially unresectable hepatocellular carcinoma: A propensity score-matching comparative study ［J］. Int J Surg, 2024, 110(5): 2545-2555. DOI: 10.1097/JS9.0000000000001155.
［21］ Sangro B, Kudo M, Erinjeri JP, et al. Durvalumab with or without bevacizumab with transarterial chemoembolisation in hepatocellular carcinoma (EMERALD-1): A multiregional, randomised, double-blind, placebo-controlled, phase 3 study ［J］. Lancet，2025，405(10474): 216-232. DOI: 10.1016/S0140-6736(24)02551-0.
［22］ Kudo M, Ren Z, Guo Y, et al. Transarterial chemoembolisation combined with lenvatinib plus pembrolizumab versus dual placebo for unresectable, non-metastatic hepatocellular carcinoma (LEAP-012): A multicentre, randomised, double-blind, phase 3 study ［J］. Lancet, 2025，405(10474): 203-215. DOI: 10.1016/S0140-6736(24)02575-3.
［23］ Rimassa L, Chan SL, Sangro B, et al. 947MO Five-year overall survival (OS) and OS by tumour response measures from the phase Ⅲ HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma (uHCC) ［J］. Ann Oncol, 2024, 35：S656. DOI: 10.1016/j.annonc.2024.08.1007.
［24］ Yau T, Galle PR, Decaens T, et al. Nivolumab plus ipilimumab versus lenvatinib or sorafenib as first-line treatment for unresectable hepatocellular carcinoma (CheckMate 9DW): an open-label, randomised, phase 3 trial［J］. Lancet，2025，405(10492): 1851-1864. DOI:10.1016/S0140-6736(25)00403-9
［25］ Zhou Y, Li J, Ying J. Anti-PD-1/L1 antibody plus anti-VEGF antibody vs. plus VEGFR-targeted TKI as first-line therapy for unresectable hepatocellular carcinoma: A network Meta-analysis ［J］. Explor Target Antitumor Ther, 2024, 5(3): 568-580. DOI: 10.37349/etat.2024.00236.
［26］ Vogel A, Chan SL, Ren Z, et al. Camrelizumab plus rivoceranib vs sorafenib as first-line therapy for unresectable hepatocellular carcinoma (uHCC): Final overall survival analysis of the phase 3 CARES-310 study ［J］. J Clin Oncol, 2024, 42(suppl16): 4110. DOI: 10.1200/JCO.2024.42.16_suppl.4110.
［27］ Zhou J, Bai L, Luo J, et al. Anlotinib plus penpulimab versus sorafenib in the first-line treatment of unresectable hepatocellular carcinoma (APOLLO): A randomised, controlled, phase 3 trial［J］. Lancet Oncol，2025，26(6): 719-731. DOI:10.1016/S1470-2045(25)00190-1.
［28］ Xu D, Wang H, Bao Q, et al. The anti-PD-L1/CTLA-4 bispecific antibody KN046 plus lenvatinib in advanced unresectable or metastatic hepatocellular carcinoma: A phase Ⅱ trial ［J］. Nat Commun, 2025, 16(1): 1443. DOI: 10.1038/s41467-025-56537-y.
［29］ Qin S, Fan J, Yang F, et al. LBA38 Iparomlimab and tuvonralimab (QL1706) with bevacizumab and/or chemotherapy in first-line (1L) treatment of advanced hepatocellular carcinoma (aHCC): A randomized, open-label, phase Ⅱ/Ⅲ study (DUBHE-H-308) ［J］. Ann Oncol, 2024, 35（suppl2）：1229-1230. DOI: 10.1016/j.annonc.2024.08.2278.
［30］ Pfister D, Nunez NG, Pinyol R, et al. NASH limits anti-tumour surveillance in immunotherapy-treated HCC ［J］. Nature, 2021, 592(7854): 450-456. DOI: 10.1038/s41586-021-03362-0.
［31］ Llovet J M, Castet F, Heikenwalder M, et al. Immunotherapies for hepatocellular carcinoma ［J］. Nat Rev Clin Oncol, 2022, 19(3): 151-172. DOI: 10.1038/s41571-021-00573-2.
［32］ Peng Z, Fan W, Zhu B, et al. Lenvatinib combined with transarterial chemoembolization as first-line treatment for advanced hepatocellular carcinoma: A phase Ⅲ, randomized clinical trial (LAUNCH) ［J］. J Clin Oncol, 2023, 41(1): 117-127. DOI: 10.1200/JCO.22.00392.
［33］ Jin Z, Chen J, Zhu X, et al. Immune checkpoint inhibitors and anti-vascular endothelial growth factor antibody/tyrosine kinase inhibitors with or without transarterial chemoembolization as first-line treatment for advanced hepatocellular carcinoma (CHANCE2201): A target trial emulation study ［J］. eClinicalMedicine，2024，72: 102622. DOI: 10.1016/j.eclinm.2024.102622.
［34］ Persano M, Rimini M, Toshifumi T, et al. PD-15 Sequential therapies after atezolizumab plus bevacizumab or lenvatinib first-line treatments ［J］. Ann Oncol, 2023, 34（suppl1）：6-7. DOI: 10.1016/j.annonc.2023.04.042.
［35］ Yan T, Huang C, Peng C, et al. A multi-center retrospective study on the efficacy and safety of regorafenib vs. regorafenib combined with PD-1 inhibitors as a second-line therapy in patients with advanced hepatocellular carcinoma ［J］. Ann Transl Med, 2023, 11(2): 109. DOI: 10.21037/atm-22-6614.
［36］ El-khoueiry AB, Kim TY, Blanc JF, et al. International, open-label phase 2 study of regorafenib plus pembrolizumab in patients with advanced hepatocellular carcinoma (HCC) previously treated with immune checkpoint inhibitors (ICI) ［J］. J Clin Oncol, 2024, 42(suppl16): 4007. DOI: 10.1200/JCO.2024.42.16_suppl.4007.
［37］ Chen X, Yen C, Huang P, et al. 983P Updated safety and efficacy of ABSK-011 in advanced hepatocellular carcinoma (aHCC) with FGF19 overexpression from a phase I study ［J］. Ann Oncol, 2024, 35（suppl2）：S671. DOI: 10.1016/j.annonc.2024.08.1043.
［38］ Sinn DH, Choi GS, Park HC, et al. Multidisciplinary approach is associated with improved survival of hepatocellular carcinoma patients ［J］. PLoS One, 2019, 14(1): e0210730. DOI: 10.1371/journal.pone.0210730.